Literature DB >> 10826581

Preterm delivery for maternal or fetal indications: maternal morbidity, neonatal outcome and late sequelae in infants.

M Kurkinen-Räty1, M Koivisto, P Jouppila.   

Abstract

OBJECTIVE: To assess maternal morbidity, and neonatal outcome and especially long term sequelae in infants born preterm due to maternal or fetal indications.
DESIGN: Analysis of retrospective cohort.
SETTING: Oulu University Central Hospital, Finland. POPULATION: One hundred and three women, who were between the 24th and the 33rd week of pregnancy, delivered by caesarean delivery because of maternal or fetal indications. They were matched with 103 women who had spontaneous preterm delivery at corresponding gestational weeks between 1990-1997. MAIN OUTCOME MEASURES: Maternal morbidity, reasons for caesarean delivery, neonatal mortality and morbidity rates, and later development of the infants.
RESULTS: Pre-eclampsia was diagnosed in 57% of the women in the indicated group and only in one woman in the control group. All infants in the indicated group and almost a third in the control group were born by caesarean birth; the main indication was threatening fetal asphyxia. There was a significant difference in neonatal mortality rates between the groups (175 vs 78 per thousand live births in the indicated vs control infants; RR 2.3, 95% CI 1.02, 4.9) and the main cause of death was respiratory insufficiency: 64% in the indicated group and 22% in the controls; RR 2.9, 95% CI 0.8, 10. Respiratory distress syndrome occurred more often (73% vs 53%, RR 1.4, 95% CI 1.1, 1.7) and it was more severe and more complicated in infants in the indicated group, compared with those in the control group. Symptomatic chronic lung disease at one year of age was more common in infants in the indicated group than in the control group (15% vs 3%; RR 4.6, 95% CI 1.4, 15.9).
CONCLUSIONS: Not only the risks of neonatal mortality and morbidity but also long term pulmonary consequences, appear to be greater in infants born preterm by indicated delivery than in preterm infants born spontaneously at corresponding weeks.

Entities:  

Mesh:

Year:  2000        PMID: 10826581     DOI: 10.1111/j.1471-0528.2000.tb13308.x

Source DB:  PubMed          Journal:  BJOG        ISSN: 1470-0328            Impact factor:   6.531


  7 in total

1.  Singleton preterm births in korle bu teaching hospital, accra, ghana - origins and outcomes.

Authors:  K Nkyekyer; Christabel Enweronu-Laryea; T Boafor
Journal:  Ghana Med J       Date:  2006-09

2.  Preterm birth phenotypes in women with autoimmune rheumatic diseases: a population-based cohort study.

Authors:  K D Kolstad; J A Mayo; L Chung; Y Chaichian; V M Kelly; M Druzin; D K Stevenson; G M Shaw; J F Simard
Journal:  BJOG       Date:  2019-10-31       Impact factor: 6.531

3.  Subtypes of preterm birth and the risk of postneonatal death.

Authors:  Beena D Kamath-Rayne; Emily A DeFranco; Ethan Chung; Aimin Chen
Journal:  J Pediatr       Date:  2012-08-09       Impact factor: 4.406

4.  Initial respiratory management in preterm infants and bronchopulmonary dysplasia.

Authors:  Ester Sanz López; Elena Maderuelo Rodríguez; Cristina Ramos Navarro; Manuel Sánchez-Luna
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Association between maternal comorbidity and preterm birth by severity and clinical subtype: retrospective cohort study.

Authors:  Nathalie Auger; Thi Uyen Nhi Le; Alison L Park; Zhong-Cheng Luo
Journal:  BMC Pregnancy Childbirth       Date:  2011-10-04       Impact factor: 3.007

6.  Preeclampsia and the risk of bronchopulmonary dysplasia in VLBW infants: a population based study.

Authors:  Ting-An Yen; Hwai-I Yang; Wu-Shiun Hsieh; Hung-Chieh Chou; Chien-Yi Chen; Kuo-Inn Tsou; Po-Nien Tsao
Journal:  PLoS One       Date:  2013-09-20       Impact factor: 3.240

7.  Fetal Outcomes in Preterm Cesarean Sections.

Authors:  Sundus Rahman; Mohib Ullah; Asma Ali; Nighat Afridi; Humaira Bashir; Zahra Amjad; Aliya Jafri; Areeba Jawaid
Journal:  Cureus       Date:  2022-08-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.